Company intelligence / Profile preview

AID Genomics

Rehovot, Center District, Israelaidgenomics.com ↗

Ownership: Private
Employees: ~250
Development stage: Commercial

Overview

AID Genomics offers commercialized genomic testing platforms for early cancer detection as well as hereditary rare disease and infectious disease diagnostics. The company leverages advanced bioinformatics and AI to improve accuracy of results. Clinical performance data are not detailed publicly but the company positions its offerings as improving survival rates through earlier detection.

Therapeutic areas: OncologyRare DiseasesInfectious Diseases
Modalities: Diagnostic test (genomic and genetic testing)Artificial intelligence-based diagnosticsBioinformatics platform
Industry: Molecular Diagnostics

Drug pipeline

3 assets

GENESORT DETECT

Commercial

Indications: Cancer

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on AID Genomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AID Genomics.

Explore the full profile